Novo Nordisk Pharma GmbH secures contract for Pharmaceutical products - Agreement in accordance with Section 130c Paragraph 1 SGB V on the granting of discounts for patent-protected drugs with the active ingredients Turoctocog alfa (NovoEight(r)) and Turoctocog alfa pegol (Esperoct(r))

Germany, Sept. 29 -- Germany based Novo Nordisk Pharma GmbH has secured contract from AOK Baden-Wurttemberg for Pharmaceutical products - Agreement in accordance with Section 130c Paragraph 1 SGB V on the granting of discounts for patent-protected drugs with the active ingredients Turoctocog alfa (NovoEight(r)) and Turoctocog alfa pegol (Esperoct(r)). The value of the contract is not disclosed.

Published by HT Digital Content Services with permission from Pivotal Sources....